PLoS ONE (2018)
Update date:2022-08-05
Topics:
Mádrová, Lucie
Krijt, Matyá?
Bare?ová, Veronika
Václavík, Jan
Friedecky, David
Dobe?ová, Dana
Sou?ková, Olga
?kopová, Václava
Adam, Tomá?
Zikánová, Marie
Purines are essential molecules for all forms of life. In addition to constituting a backbone of DNA and RNA, purines play roles in many metabolic pathways, such as energy utilization, regulation of enzyme activity, and cell signaling. The supply of purines is provided by two pathways: the salvage pathway and de novo synthesis. Although purine de novo synthesis (PDNS) activity varies during the cell cycle, this pathway represents an important source of purines, especially for rapidly dividing cells. A method for the detailed study of PDNS is lacking for analytical reasons (sensitivity) and because of the commercial unavailability of the compounds. The aim was to fully describe the mass spectrometric fragmentation behavior of newly synthesized PDNS-related metabolites and develop an analytical method. Except for four initial ribotide PDNS intermediates that preferentially lost water or phosphate or cleaved the forming base of the purine ring, all the other metabolites studied cleaved the gly-cosidic bond in the first fragmentation stage. Fragmentation was possible in the third to sixth stages. A liquid chromatography-high-resolution mass spectrometric method was developed and applied in the analysis of CRISPR-Cas9 genome-edited HeLa cells deficient in the individual enzymatic steps of PDNS and the salvage pathway. The identities of the newly synthesized intermediates of PDNS were confirmed by comparing the fragmentation patterns of the synthesized metabolites with those produced by cells (formed under pathological conditions of known and theoretically possible defects of PDNS). The use of stable isotope incorporation allowed the confirmation of fragmentation mechanisms and provided data for future fluxomic experiments. This method may find uses in the diagnosis of PDNS disorders, the investigation of purinosome formation, cancer research, enzyme inhibition studies, and other applications.
View MoreShangHai Original Economy-Trade Develop Co.,Ltd.,
Contact:86-21-68552131
Address:shanghai
Jiangsu Taihu New Materials Holding Co., Ltd
Contact:+86-519-86160108
Address:Xueyan Town, Changzhou City, Jiangsu Province, 213169, China
Shanghai AoBo Bio-Pharmaceutical Technology Co., Ltd.
Contact:+86-21-51320130-801, 816
Address:Room 601, No. 1011, Halei Road, Zhangjiang High-Tech Park, Pudong, Shanghai
Anhui Xinyuan Technology Co.,Ltd
website:http://www.ahxytech.com/
Contact:0086-559-3515800
Address:Huangshan City of Anhui Province Huizhou Huizhou District Road, 21-9
Chengdu Aslee Biopharmaceuticals, Inc
Contact:18608018419
Address:Chengdu Aslee Biopharmaceuticals, Inc
Doi:10.1016/j.bmc.2015.02.051
(2015)Doi:10.1016/j.bmcl.2021.127845
(2021)Doi:10.1021/jo000209v
(2000)Doi:10.1021/ja01289a061
(1937)Doi:10.1016/S0022-328X(00)00227-8
(2000)Doi:10.1016/S0040-4039(00)00261-6
(2000)